Prime Medicine’s Prime Editor PM-577a cleared regulatory requirements to begin clinical testing for Wilson’s disease. The company said the New Zealand authority Medsafe approved its clinical trial application for the investigational editor program. PM-577a represents Prime Medicine’s approach to use prime editing to address a genetic driver in Wilson’s disease, advancing the program beyond development into patient dosing. The company’s timing suggests it is building momentum toward first clinical readouts for the platform in a targeted genetic indication. For the gene-editing space, Wilson’s disease provides a high-profile setting where durable correction could translate into meaningful clinical benefit, while also testing the translation of prime editing from preclinical models into clinical safety and feasibility. The approval adds another datapoint to the growing pipeline of precision editing therapeutics moving into early-phase human studies.